Zacks: Brokerages Expect Unum Therapeutics Inc (NASDAQ:UMRX) Will Post Quarterly Sales of $3.11 Million

Equities analysts forecast that Unum Therapeutics Inc (NASDAQ:UMRX) will announce sales of $3.11 million for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Unum Therapeutics’ earnings, with estimates ranging from $1.80 million to $4.41 million. Unum Therapeutics posted sales of $2.04 million in the same quarter last year, which would indicate a positive year over year growth rate of 52.5%. The company is expected to report its next earnings results on Monday, November 11th.

On average, analysts expect that Unum Therapeutics will report full year sales of $13.85 million for the current financial year, with estimates ranging from $9.70 million to $17.60 million. For the next year, analysts expect that the firm will post sales of $16.91 million, with estimates ranging from $9.00 million to $25.33 million. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that follow Unum Therapeutics.

Unum Therapeutics (NASDAQ:UMRX) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.34) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.39) by $0.05. Unum Therapeutics had a negative net margin of 340.49% and a negative return on equity of 69.43%. The company had revenue of $3.14 million for the quarter, compared to analyst estimates of $3.10 million.

A number of equities analysts have commented on UMRX shares. ValuEngine upgraded shares of Unum Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Wedbush decreased their price target on shares of Unum Therapeutics from $20.00 to $13.00 and set an “outperform” rating for the company in a research report on Tuesday. They noted that the move was a valuation call. Zacks Investment Research raised shares of Unum Therapeutics from a “hold” rating to a “buy” rating and set a $4.00 price target for the company in a research report on Friday, April 26th. SunTrust Banks decreased their price target on shares of Unum Therapeutics to $6.00 and set a “buy” rating for the company in a research report on Wednesday, July 3rd. Finally, Cowen reissued a “hold” rating on shares of Unum Therapeutics in a research report on Monday. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Unum Therapeutics currently has an average rating of “Buy” and a consensus price target of $12.40.

UMRX stock traded down $0.06 on Friday, hitting $1.75. The company’s stock had a trading volume of 81,212 shares, compared to its average volume of 142,328. The firm’s 50 day simple moving average is $2.23. Unum Therapeutics has a 1 year low of $1.50 and a 1 year high of $16.72. The stock has a market capitalization of $53.91 million, a PE ratio of -1.26 and a beta of 1.38. The company has a current ratio of 2.65, a quick ratio of 2.65 and a debt-to-equity ratio of 0.11.

Hedge funds have recently modified their holdings of the company. BlackRock Inc. lifted its stake in shares of Unum Therapeutics by 281.5% during the fourth quarter. BlackRock Inc. now owns 1,530,419 shares of the company’s stock valued at $6,733,000 after acquiring an additional 1,129,262 shares during the period. Northern Trust Corp increased its holdings in Unum Therapeutics by 312.6% during the 4th quarter. Northern Trust Corp now owns 178,640 shares of the company’s stock worth $786,000 after purchasing an additional 135,345 shares in the last quarter. Wasatch Advisors Inc. increased its holdings in Unum Therapeutics by 64.5% during the 1st quarter. Wasatch Advisors Inc. now owns 254,449 shares of the company’s stock worth $1,117,000 after purchasing an additional 99,814 shares in the last quarter. Paloma Partners Management Co bought a new stake in Unum Therapeutics during the 2nd quarter worth approximately $227,000. Finally, Geode Capital Management LLC increased its holdings in Unum Therapeutics by 85.4% during the 4th quarter. Geode Capital Management LLC now owns 132,565 shares of the company’s stock worth $583,000 after purchasing an additional 61,061 shares in the last quarter. Institutional investors own 47.16% of the company’s stock.

About Unum Therapeutics

Unum Therapeutics Inc, a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The company's lead product candidate is the ACTR707 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory CD20+ B cell non-Hodgkin lymphoma (r/r NHL).

See Also: How to execute a trade ex-dividend strategy?

Get a free copy of the Zacks research report on Unum Therapeutics (UMRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Unum Therapeutics (NASDAQ:UMRX)

Receive News & Ratings for Unum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.